

A Long-Term Extension Study of JNJ-77242113 in Participants with Moderate-to-Severe Plaque Psoriasis

Submission date 03/08/2022	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 11/10/2022	Overall study status Completed	<input type="checkbox"/> Protocol <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 09/08/2024	Condition category Skin and Connective Tissue Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Plaque psoriasis is a common, chronic, inflammatory condition, affecting about 3.5 million patients in the United States, European Union, and Japan. Despite advanced treatment options, large numbers of patients are not receiving these therapies. There is a need for safer options, fewer injections, and more effective oral medications. Janssen has an investigational drug called JNJ-77242113, which targets immune responses in the body and skin that impact diseases, such as psoriasis. It is hoped that targeting immune response processes may lead to less inflammation and a reduction in psoriasis disease activity.

This study is a follow-on trial of 77242113PSO2001 (<https://www.isrctn.com/ISRCTN76915275>), which is designed to evaluate long-term efficacy and safety of the investigational drug JNJ-77242113 in adults with moderate to severe plaque psoriasis.

Who can participate?

Patients who have completed the week 16 weeks in the study 77242113PSO2001 and who, in the opinion of the investigator, may benefit from inclusion in this long-term extension study.

What does the study involve?

This is a long-term extension study of JNJ-77242113 in eligible participants who completed the Week 16 visit of the originating 77242113PSO2001 study. All participants will receive active JNJ-77242113 study medication. The total study duration will be up to 40 weeks which will include:

1. A 36-week treatment period
2. A 4-week safety follow-up period after the last study intervention administration

Safety will be assessed by clinical safety laboratory assessments, electrocardiograms (ECGs), vital signs, physical examinations, and monitoring adverse events (AEs) throughout the study.

What are the possible benefits and risks of participating?

Possible benefits for patients taking JNJ-77242113 include improvements in plaque psoriasis symptoms based on current scientific theory. Only patients who may benefit from such drug

treatment (i.e., with specific disease characteristics identified by study investigators) are eligible for study inclusion. Such patient participation may help other psoriasis patients in the future.

Study participants also may experience some benefits not due to receiving the study drug, but instead due to regular visits, assessments, and overall health monitoring. Long-term benefits, however, are not guaranteed to happen and there may not be any benefit to participants by being in this study.

Not all possible side effects and risks related to JNJ-77242113 are known, such that unexpected side effects may arise or be life-threatening.

A participant information sheet (which will be signed by every participant agreeing to participate in the study) includes a detailed section outlining all known risks/side effects to study participants.

To minimize any study-associated risks participants are frequently reviewed at every visit for side effects and adverse events and participants are educated to report any such problems to the study staff without delay.

Any serious adverse events that are reported to the sponsor are thoroughly reviewed by a specialist drug safety team and the sponsor has implemented an Independent Data Review Committee.

Where is the study run from?

Janssen-Cilag International NV (Belgium) is the sponsor for this study. The study will be run at multiple healthcare locations both within the UK and around the world.

When is the study starting and how long is it expected to run for?

June 2022 to November 2023

Who is funding the study?

Janssen Research and Development, LLC (USA)

Who is the main contact?

Sarah Currie, JanssenUKRegistryQueries@its.jnj.com

Contact information

Type(s)

Scientific

Contact name

Dr Medical Information and Product Information Enquiry

Contact details

50-100 Holmers Farm Way

High Wycombe

United Kingdom

HP12 4DP

+44 (0)800 731 8450

medinfo@its.jnj.com

Type(s)

Principal investigator

Contact name

Dr Andrew Pink

Contact details

Guy's Hospital
Great Maze Pond
London
United Kingdom
London

Additional identifiers**Clinical Trials Information System (CTIS)**

2021-004320-16

Integrated Research Application System (IRAS)

1005014

ClinicalTrials.gov (NCT)

NCT05364554

Protocol serial number

IRAS 1005014, 77242113PSO2002, CPMS 52237

Study information**Scientific Title**

A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis.

Acronym

FRONTIER 2

Study objectives

Main objectives:

1. To evaluate long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis

Secondary objectives:

1. To evaluate and assess additional long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis
2. To evaluate and assess the effect of JNJ-77242113 treatment on patient-reported psoriasis severity in participants with moderate-to-severe plaque psoriasis
3. To evaluate and assess the safety and tolerability of JNJ-77242113 in participants with moderate-to-severe plaque psoriasis

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 03/08/2022, South Central - Berkshire B Research Ethics Committee (Meeting held by video-conference via Zoom; +44 (0)207 104 8253, +44 (0)207 104 8068, +44 (0)207 104 8276; berkshireb.rec@hra.nhs.uk), ref: 22/SC/0224

Study design

Multicentre, long-term extension, double-blind, dose-ranging, parallel group, randomized interventional study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Plaque psoriasis

Interventions

The total duration of this study is up to 40 weeks which includes a 36-week treatment period, and a 4-week safety follow-up period. Participants will continue to receive the dose randomly assigned by the online interactive web randomisation system tool from the preceding study (77242113PSO2001).

Those participants assigned to the placebo treatment arm in the preceding study will be assigned to an active treatment arm in this study. Each active cohort group will also receive placebo to maintain blinding of dose regimens throughout the trial:

1. Group 1 will receive dose 1 of JNJ-77242113 once daily and placebo
2. Group 2 will receive dose 2 of JNJ-77242113 once daily and placebo
3. Group 3 will receive dose 3 of JNJ-77242113 once daily and placebo
4. Group 4 will receive dose 1 of JNJ-77242113 twice daily and placebo
5. Group 5 will receive dose 3 of JNJ-77242113 twice daily and placebo
6. Group 6 will receive dose 3 of JNJ-77242113 once daily and placebo

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

JNJ-77242113

Primary outcome(s)

Percentage of participants achieving Psoriasis Area Severity Index (PASI) 75 score ($\geq 75\%$ improvement in PASI from baseline of the originating study [77242113PSO2001]) at Week 36. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk,

upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.

Key secondary outcome(s)

1. Percentage of participants achieving PASI 90 score ($\geq 90\%$ improvement in PASI from baseline of the originating study [77242113PSO2001]) at week 36
2. Percentage of participants achieving PASI 100 score ($\geq 100\%$ improvement in PASI from baseline of the originating study [77242113PSO2001]) at week 36
3. Change from baseline of the originating study (77242113PSO2001) in PASI Total Score at Week 36
4. Percentage of participants achieving an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) determined at Week 36. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
5. Change from baseline of originating study (77242113PSO2001) in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores reported at Week 36. The PSSD includes a patient-reported outcome (PRO) questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two subscores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
6. Change from baseline of originating study (77242113PSO2001) in Psoriasis Symptoms and Signs Diary (PSSD) Signs Scores reported at Week 36
7. Percentage of participants achieving PSSD Symptoms Score of 0 at Week 36 among participants with a baseline (in the originating study 77242113PSO2001) symptoms score ≥ 1
8. Percentage of participants achieving PSSD Signs Score of 0 at Week 36 among participants with a baseline (in the originating study 77242113PSO2001) signs score ≥ 1
9. Number of participants with Adverse Events (AEs) monitored up to Week 40. An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
10. Number of participants with Serious Adverse Events (SAEs) monitored up to Week 40. SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

Completion date

13/11/2023

Eligibility

Key inclusion criteria

1. Must have completed the Week 16 visit in Protocol 77232114PSO2001
2. In the opinion of the investigator, may benefit from inclusion in this long-term extension (LTE)

study

3. Must agree to avoid prolonged sun exposure and avoid the use of tanning booths or other ultraviolet light sources during the study
4. Must agree to discontinue all topical therapies that could affect psoriasis or the psoriasis area severity index (PASI) or Investigator's global assessment (IGA) evaluation, other than nonmedicated emollient and salicylic acid shampoos, prior to first administration of study intervention.
5. Agree not to receive a live virus or live bacterial vaccination during the study, or within 4 weeks after the last administration of the study intervention

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

227

Key exclusion criteria

1. Was permanently discontinued from study intervention in Protocol 77242113PSO2001 for any reason
2. Has received any biologic therapy or experimental therapy since completion of the originating study 77242113PSO2001
3. Has received any live virus or bacterial vaccination within 12 weeks before the first administration of study intervention
4. Has received the bacille Clamette-Guerin (BCG) vaccine within 12 months of the first administration of study intervention
5. Currently has hepatitis B surface antigen (HBsAg) or hepatitis C antibody (antiHCV) positive, or has another clinically active liver disease, or tests positive for HBsAg or anti-HCV

Date of first enrolment

10/06/2022

Date of final enrolment

06/02/2023

Locations

Countries of recruitment

United Kingdom

Canada

France

Germany

Japan

Korea, South

Poland

Spain

Taiwan

United States of America

Study participating centre

Innovaderm Research Inc.

3530 boulevard Saint-Laurent
Montreal
Canada
H2H2B5

Study participating centre

Skin Centre for Dermatology

775 Monaghan Road
Peterborough
Canada
K9J 5K2

Study participating centre

Dr. Chih-ho Hong Medical Inc.

15300 105 Ave
Surrey
Canada
V3R 6A7

Study participating centre

DermEdge Research

333 Lakeshore Road West
Mississauga
Canada
L4Y 4C5

Study participating centre
K. Papp Clinical Research
135 Union Street East
Waterloo
Canada
N2J 1C4

Study participating centre
Dermatology Research Institute Inc.
8500 Blackfoot Trail SE
Calgary
Canada
T2J 7E1

Study participating centre
XLR8 Medical Research
2425 Tecumseh Road East
Windsor
Canada
N8W 1E6

Study participating centre
Dermaterials Research
25 Charlton Avenue East
Hamilton
Canada
L8N 1Y2

Study participating centre
Universitätsklinikum Carl Gustav Carus Dresden
Fetscherstr. 74
Dresden
Germany
1307

Study participating centre
MensingDerma research GmbH
Heegbarg 4
Hamburg

Germany
22391

Study participating centre
Universitätsklinikum Schleswig-Holstein - Kiel
Arnold-Heller-Str. 3, Haus 19
Kiel
Germany
24105

Study participating centre
Praxis für Dermatologie und Venerologie
Hauptstrasse 36a
Dresden
Germany
1097

Study participating centre
Rothhaar Studien GmbH
Dermatologisches Studienzentrum
Berlin
Germany
10783

Study participating centre
Hautarztpraxis
Annenstraße 151
Witten
Germany
58453

Study participating centre
Uniklinik Münster -Klinik u. Pol. f. Hautkrankheiten
Von-Esmarch-Straße 58
Munster
Germany
48149

Study participating centre

Niesmann & Othlinghaus GbR
Alleestraße 80
Bochum
Germany
44793

Study participating centre
Universitätsklinikum Frankfurt
Theodor-Stern-Kai 7
Frankfurt am Main
Germany
60590

Study participating centre
Universitätsklinikum Heidelberg Im Neuenheimer
Feld 440
Heidelberg
Germany
69120

Study participating centre
Gemeinschaftspraxis Scholz/Sebastian/Schilling
Am Bahnhof 1
Mahlow
Germany
15831

Study participating centre
ISA - Interdisciplinary Study Association GmbH
Rankestrasse 34
Berlin
Germany
10789

Study participating centre
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Langenbeckstrasse 1
Mainz
Germany
55131

Study participating centre
Fachklinik Bad Bentheim
Am Bade 1
Bad Bentheim
Germany
48455

Study participating centre
Rosenpark Research GmbH
Rheinstrasse 14
Darmstadt
Germany
64283

Study participating centre
Universitätsklinikum Bonn
Klinik und Poliklinik für Dermatologie und Allergologie
Bonn
Germany
53127

Study participating centre
Derma-Study-Center Friedrichshafen GmbH
Charlottenstrasse 12/1
Friedrichshafen
Germany
88045

Study participating centre
Hosp. Univ. I Politecni La Fe
106 Avinguda de Fernando Abril Martorell
Valencia
Spain
46026

Study participating centre
Hosp. Univ. 12 De Octubre
Avda. Cordoba sn
Madrid

Spain
28041

Study participating centre
Hosp. Univ. Germans Trias I Pujol
Carretera de Canyet s/n
Badalona
Spain
8916

Study participating centre
Hosp. De Manises
Av. de la Generalitat Valenciana, 50
Valencia
Spain
46940

Study participating centre
Hosp. Univ. De Cruces
Plaza de Cruces, s/n
Barakaldo
Spain
48903

Study participating centre
Hosp. Reina Sofia
C/ Menéndez Pidal s/n
Córdoba
Spain
14004

Study participating centre
Hosp. Univ. De Basurto
Avenida de Montevideo, 18
Bilbao
Spain
48013

Study participating centre

HIA Sainte Anne
2 boulevard Sainte Anne
Toulon
France
83800

Study participating centre
Hopital Charles Nicolle
1 rue de Germont
Rouen
France
76031

Study participating centre
Centre Hospitalier Le Mans
194 Avenue Rubillard
Le Mans
France
72037

Study participating centre
Guy's and St Thomas' NHS Foundation Trust
Great Maze Pond
London
United Kingdom
SE1 9RT

Study participating centre
University Hospital Southampton NHS Foundation Trust
Tremona Road
Southampton
United Kingdom
SO16 6YD

Study participating centre
Kume Clinic
1-65-2, Otorihigashimachi, Nishi Ku
Osaka Fu
Japan
593-8324

Study participating centre

Sapporo Skin Clinic

2-1-1 Minami-3Jo Nishi

Sapporo

Japan

060-0063

Study participating centre

Takagi Dermatology Clinic

Nishi-sanjo Minami 4-16

Obihiro-shi

Japan

080-0013

Study participating centre

Nomura Dermatology Clinic

4-27-14 tanmachi

Yokohama

Japan

221-0825

Study participating centre

Shizuoka Prefectural General Hospital

4-27-1, Kitaando, Aoi-ku

Shizuoka

Japan

420-8527

Study participating centre

Shirasaki Dermatology Clinic

3-5-33 Ekinan

Takaoka

Japan

933-0871

Study participating centre

Toyama Prefectural Central Hospital

2-2-78 Nishinagae Toyama-shi

Toyama

Japan
930-8550

Study participating centre
Seoul National University Bundang Hospital
82, Gumi-ro 173beon-gil
Gyeonggi-do
Korea, South
13620

Study participating centre
Konkuk University Medical Center
120-1 NeunGdong-ro, Gwangjin-Gu
Seoul
Korea, South
5030

Study participating centre
Pusan National University Hospital
179 Gudeok-Ro
Busan
Korea, South
49241

Study participating centre
KyungHee University Hospital
23 Kyungheedaero
Seoul
Korea, South
102-1703

Study participating centre
Asan Medical Center
88, Olympic-ro 43-gil, Songpa-gu,
Seoul
Korea, South
5505

Study participating centre

Seoul National University Hospital

101, Daehak-ro
Seoul
Korea, South
3080

Study participating centre

Severance Hospital, Yonsei University Health System

50-1, Yonsei-ro, Seodaemun-gu
Seoul
Korea, South
3722

Study participating centre

WROMEDICA

Mickiewicza 91
Wroclaw
Poland
51-685

Study participating centre

DermaDent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski s.c.

Tuberozy 3
Osielsko
Poland
86031

Study participating centre

Nzoz Zdrowie Osteo-Medic

ul. Wiejska 81
Bialystok
Poland
15-351

Study participating centre

Dermed Centrum Medyczne Sp. z o.o

ul. Piotrkowska 48
Lodz
Poland
90-265

Study participating centre
Royalderm Agnieszka Nawrocka
K.Kieślowskiego 3B/3
Warszawa
Poland
2962

Study participating centre
Klinika Ambroziak Estederm Sp. z o.o
Kosiarzy 9A
Warszawa
Poland
02-953

Study participating centre
NZOZ Specderm
Kardynała Stefana Wyszyńskiego 10 lokal 11
Białystok
Poland
15-888

Study participating centre
Diamond Clinic Specjalistyczne Poradnie Lekarskie
Stefana Rogozińskiego 6/U3
Kraków
Poland
31-559

Study participating centre
National Taiwan University Hospital
No.1, Changde Street
Taipei City
Taiwan
10048

Study participating centre
Chang-Gung Memorial Hospital, LinKou Branch
No.5 Fuxing street
Taoyuan

Taiwan
333

Study participating centre
National Cheng Kung University Hospital
138 Sheng-Li Rd
Tainan
Taiwan
704

Study participating centre
Chang Gung Memorial Hospital
Kaohsiung Branch
Kaohsiung
Taiwan
83342

Study participating centre
Windsor Dermatology, PC
59 One Mile Rd Ext Ste G
East Windsor
United States of America
8520

Study participating centre
Arlington Dermatology
5301 Keystone Ct.
Rolling Meadows
United States of America
60008

Study participating centre
Modern Research Associates
9101 N. Central Expressway
Dallas
United States of America
75231

Study participating centre

Renstar Medical Research
21 NE 1st Ave
Ocala
United States of America
34470

Study participating centre
University of Pittsburgh Department of Dermatology
3601 5th Ave
Pittsburgh
United States of America
15213

Study participating centre
Forcare Clinical Research, Inc.
15416 North Florida Avenue
Tampa
United States of America
33613

Study participating centre
Indiana Clinical Trial Center
824 Edwards Drive
Plainfield
United States of America
46168

Study participating centre
Oregon Dermatology and Research Center
2565 NW Lovejoy
Portland
United States of America
97210

Study participating centre
Center for Clinical Studies
1401 Binz Street
Houston
United States of America
77004

Study participating centre
Center for Clinical Studies
451 North Texas Avenue
Webster
United States of America
77598

Study participating centre
Hamzavi Dermatology
2950 Keewahdin Road
Fort Gratiot
United States of America
48059

Study participating centre
Vivida Dermatology
2110 East Flamingo Road, Suite 213
Las Vegas
United States of America
89119

Study participating centre
Pacific Skin Institute
1495 River Park Drive
Sacramento
United States of America
95815

Study participating centre
Synergy Clinical Research
595 Buckingham Way
San Francisco
United States of America
94132

Study participating centre
Premier Clinical Research
324 South Sherman
Spokane

United States of America
99202

Sponsor information

Organisation

Janssen (Belgium)

ROR

<https://ror.org/04yzcpd71>

Funder(s)

Funder type

Industry

Funder Name

Janssen Research and Development

Alternative Name(s)

Janssen R&D, Janssen Research & Development, Janssen Research & Development, LLC, Janssen Research & Development LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Research & Development at Janssen, JRD, J&J PRD

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request. The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at <https://www.janssen.com/clinicaltrials/transparency>. As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at yoda.yale.edu

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No
Other unpublished results	Immunogenicity results have been redacted		09/08/2024	No	No